10-year Trends in #HeartFailure among Patients with #Dialysis and Non-dialysis #CKD #VisualAbstract by Husam Alzayer https://www.kireports.org/article/S2468-0249(26)02927-X/fulltext
Cristina Popa
@nephroseeker.medsky.social
🩺 Nephrologist = kidney philosopher 📜History lover 🕊️ Aspiring to be better. Freethinker 📍 #NephJC editor-in-chief 📍@KIreportsbsky.social 📍ERAkidney #ERA26 social media co-leader #NephSky #MedSky
Guidance on nutrition supplementation in dialysis www.kireports.org/article/S246... In @kireports.bsky.social Increasing protein intake once dialysis begins is important!
Want more?? #NephSky #NephJC 🩳FIND-CKD shorts from @CristinaDeReins Finerenone in glomerulonephritis & a pooled analysis of safety and efficacy in CKD (INFINITY) www.nephjc.com/news/2026/7/20/finerenone-shorts
Finerenone across the proteinuric CKD spectrum — NephJC
Cristina Popa dissects the FIND-CKD extras: GN subgroup and INFINITY analysis
nephjc.com
I want more info: www.nephjc.com/news/2026/7/... www.nephjc.com/news/2026/7/... @manoleaandreea.bsky.social @divyaveerssneph.bsky.social @rnflex.bsky.social @drbarbateba.bsky.social 9/10
Finerenone across the proteinuric CKD spectrum — NephJC
Cristina Popa dissects the FIND-CKD extras: GN subgroup and INFINITY analysis
nephjc.com
👀 Seek and you shall FIND 🔎 #ERA26 #NephSky FIND-CKD asks if finerenone is beneficial in patients with non-diabetic CKD. Blog by @manoleaandreea.bsky.social & @divyaveerssneph.bsky.social www.nephjc.com/news/2026/7/6/find-ckd
Beyond Diabetic Kidney Disease: FIND-ing Finerenone's Next Role — NephJC
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effect...
nephjc.com
#NephJC Shorts is our new way to share quick takes on notable studies we can’t cover fully 👇👇Check the updated blog page for upcoming Shorts and those already published ✨Suggestions and feedback welcome www.nephjc.com/nephjc-shorts
NephJC Shorts — NephJC
nephjc.com
#NephJC #TenPostNephJC. #NephSky 1/10 Patients with CKD have ⬆️ CVD & bleeding risks but are often excluded from antithrombotic trials, creating a 🔑 evidence gap. Can low dose rivaroxaban safely improve CV outcomes? pubmed.ncbi.nlm.nih.gov/42240165/
🚆 TRACK trial: If thrombosis is at the core of 🫀disease...then DOACs might be helpful in high-risk CKD pts? Maybeeeee... #Nephsky Blog by @nephroseeker.medsky.social & @drsaivani.bsky.social www.nephjc.com/news/2026/7/6/on-the-right-track-rivaroxaban-to-prevent-cardiovascular-events-in-advanced-ckd
On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD. — NephJC
Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD. Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown ben...
nephjc.com
A #NephJC short of the telitacicept trial from @nephromommy-akshu.bsky.social www.nephjc.com/news/2026/sh... IMO the exciting part of the early signal of GFR stabilization - if this is recapitulated with atacicept and sibeprelimab - then we can truly say IgAN remission is here and achievable
NephJC Short: When BAFF Meets APRIL: Telitacicept in IgA Nephropathy (TELIGAN trial) — NephJC
Does Dual BAFF/APRIL Blockade with Telitacicept Reduce Proteinuria in Persistent Proteinuric IgA Nephropathy?
nephjc.com
Meeting number 2 is in the books. 🧑🏫We reviewed how to blog, create a VA, create a post thread and promote on Insta. So many ways to learn and teach #NephJC #NephSky @dramiliflores.bsky.social @drpallaviprasad.bsky.social @nephroseeker.medsky.social @hswapnil.medsky.social @brianrifkin.bsky.social
The second issue of the journal is live! @theisn.org @arvindcanchi.bsky.social Thanks to the authors, and our reviewers! Everything open access to read: www.kicasereports.org/issue/S3117-... #KICR
🧂New @freelyfiltered.bsky.social episode on hyponatremia correction #NephJC 🍾How can Brussels champagne help with hypoNa? 🎙️ Special invites: Ewot Hoorn @bettercallseeth.bsky.social 🎙️Filtrate: @kidneyboy.bsky.social @hswapnil.medsky.social @nephcrit.bsky.social www.nephjc.com/freelyfilter...
FF93 Hyponatremia Interventional Trial — NephJC
Time to fix the sodium! The Hyponatremia Intervention Trial
nephjc.com
And @nejm.org retracts ADVOCATE based on the FDA uncovering and 2 academic authors asking for article to be pulled. (Good on them!) www.nejm.org/doi/10.1056/... h/t @drjmluther.bsky.social #Avacopan #vasculitis
Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609. | NEJM
The two academic authors of the article by Jayne et al., Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609,1 request retraction of the article because, accordi...
nejm.org
Swapnil Hiremath 🍁🇨🇦@hswapnil.medsky.social · last mo.With link this time www.medscape.com/viewarticle/...
🦵Had our Kick-off meeting today to welcome a new class of #NephJC interns (year 12 and counting). 👁️Keep an eye out for new blog and VA creators. See if you can Catch'em All🎣 #NephSky #MedSky @hswapnil.medsky.social @kidneyboy.bsky.social @nephroseeker.medsky.social @dramiliflores.bsky.social
💡Nephrology inpatient volume increased 44%, outpacing other specialties ⏮️ Retrospective, 62 million admissions over 10 yrs 📍Patients became more complex: ⬆️multidisciplinary care, frailty& poorer primary care access 📍Complexity increased mainly independent of aging www.ajkd.org/article/S027...
El resumen visual: MAJESTRY trial 👑 @dramiliflores.bsky.social and Dr. Divya Bajpai www.nephjc.com/news/ensayomajesty #NephSky #NephJC
Majesty: El Resumen Visual — NephJC
Recién llegado desde #ERA26, el estudio MAJESTY comparó obinutuzumab frente a tacrolimus y plantea importantes interrogantes sobre el futuro de las terapias anti-CD20 en la nefropatía membranosa prima...
nephjc.com
#NephJC Consensus From GEMRITUX, MENTOR, STARMEN, RI-CYCLO & MAJESTY- the signal remains consistent: ✅ Anti-CD20 therapy works ✅ Remissions are durable ✅ Relapses are lower than CNIs Check out anti-CD20 trials in pMN by @nephroseeker.medsky.social 👇 #NephJC #TenPostNephJC #NephTwitter #NephSky
2/10 What'd I miss? 👀 📍Obinutuzumab: type II anti-CD20 monoclonal antibody, depletes B cells 📍Tacrolimus: ⬇️ T lymphocytes through FK50-binding protein 📍MAJESTY asks: 👑 Can OBI outperform TAC in durable remission while preserving kidney function? #ChatGPT #NephJC #TenPostNephJC #NephSky
1/10 With the incredible wave of glomerular disease and trials showcased at #ERA26, it's time for membranous nephropathy to take the stage Could deeper B-cell depletion finally claim the throne? 👑 Read the article 👇 pubmed.ncbi.nlm.nih.gov/42246654/ #NephJC #TenPostNephJC #NephSky
The MAJESTRY trial, OBI vs TAC in membranous nephropathy. 👑 Visual abstract by Dr. Divya Bajpai #NephSky #NephJC www.nephjc.com/news/majestytrial
Majesty: The Visual Abstract — NephJC
Fresh from the #ERA26 Late-Breaking Clinical Trials, the MAJESTY study compared obinutuzumab with tacrolimus and raises important questions about the future of anti-CD20 therapy. 👑 Is deeper B-cell d...
nephjc.com
Is it time for a new leader in membranous nephropathy, or is it just a game of thrones 👑? This week we're discussing OBI vs TAC in the MAJESTRY trial from #ERA26 🏰🐑 #NephSky We welcome back from retirement @jamiekwillows.bsky.social with the summary ✍️ www.nephjc.com/news/2026/06/22-majestyobi
Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial — NephJC
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
nephjc.com
🚨New 🩳 by @nephroseeker.medsky.social eGFRcr, eGFRcys, eGFRcr-cys, mGFR... What does mGFR teach us about estimates and outcomes? #NephSky #MedSky #NephJC www.nephjc.com/news/2026/short/measuredgfr
NephJC Short: The map and the territory: what measured GFR teaches us about our estimates — NephJC
Is measured GFR more accurate than eGFR for forecasting adverse outcomes?
nephjc.com
PowerPoint slides for the FIND-CKD primary presentation and NOW freely available – including the glomerular disease, data and INFINITY (IPD meta-analysis). Use them, adapt them, share them as you like - All FIND-CKD program presentations and publications now live at www.find-CKD.com
#TenPostNephJC #NephSky #NephJC 1/10 How often do we miss non-diabetic kidney disease (NDKD)? 🚩NDKD are 1) active urine sediment, 2) sudden worsening RFT, 3) absence of retinopathy 4) systemic symptoms like rash @glombandit.bsky.social kidney-international.org/article/S008...
✨Exciting news #NephtSky The new #NephJC editorial interns are here! 📢Give them a follow and make them feel at home 👉 @drbarbateba.bsky.social @ancast13.bsky.social @kiddokidney.bsky.social @andrewdelaat.bsky.social @farahwehbe92.bsky.social 👇👇 www.nephjc.com/news/2025/6/...
NephJC Internship 2026-2027 — NephJC
Introducing NephJC’s brand new editorial internship class of 2026-2027
nephjc.com
The LBCT line up at #ERA26 next week Day 1: TRACK is the big one (rest is phase 2 or results we know) Day 2 is FIND CKD, TURING & MAJESTY sound interesting Day 3: GOOD IDES is negative, Ravulizumab is positive 1; HDx will torture something positive I think Lots of FOMO on missing Glasgow
1/ Hey #NephSky #MedSky 👋👋 Could a very high eGFR be a warning sign, not reassurance? This #KIreports editorial reframes "supra-normal" filtration as early cardiorenal stress and makes the case for a next-generation heat map www.kireports.org/article/S246...
